Ellen M. Janssen

Ellen M. Janssen

Auto-generated profile, based on publicly available information

Ellen M. Janssen

Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2016 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
KCKei Long Cheung
Kei Long Cheung
BWBen F. M. Wijnen
Ben F. M. Wijnen
IHIlene L. Hollin
Ilene L. Hollin
EJEllen M. Janssen
Ellen M. Janssen
JBJohn F. Bridges
John F. Bridges
MHMickael Hiligsmann
Mickael Hiligsmann
Introduction Best–worst scaling (BWS) is becoming increasingly popular to elicit preferences in health care. However, little is known about current practice and trends in the use of BWS in health care. This study aimed to identify, review and critically appraise BWS in health care, and to identify trends over time in key aspects of BWS. Methods A systematic review was conducted, using Medline (via Pubmed) and EMBASE to identify all English-language BWS studies published up until April 2016. Using a predefined extraction form, two reviewers independently selected articles and critically appraised the study quality, using the Purpose, Respondents, Explanation, Findings, Significance (PREFS) checklist. Trends over time periods (≤2010, 2011, 2012, 2013, 2014 and 2015) were assessed further. Results A total of 62 BWS studies were identified, of which 26 were BWS object case studies, 29 were BWS profile case studies and seven were BWS multi-profile case studies. About two thirds of the studies were performed in the last 2 years. Decreasing sample sizes and decreasing numbers of factors in BWS object case studies, as well as use of less complicated analytical methods, were observed in recent studies. The quality of the BWS studies was generally acceptable according to the PREFS checklist, except that most studies did not indicate whether the responders were similar to the non-responders. Conclusion Use of BWS object case and BWS profile case has drastically increased in health care, especially in the last 2 years. In contrast with previous discrete-choice experiment reviews, there is increasing use of less sophisticated analytical methods.

1 May 2015 in General Hospital Psychiatry
Verified
Journal Article
Closed access
EJEllen M. Janssen
Ellen M. Janssen
EMEmma E. McGinty
Emma E. McGinty
SASusan T. Azrin
Susan T. Azrin
DJDenise Juliano-Bult
Denise Juliano-Bult
GDGail L. Daumit
Gail L. Daumit

23 October 2017 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
EJEllen M. Janssen
Ellen M. Janssen
DMDeborah A Marshall
Deborah A Marshall
AHA. Brett Hauber
A. Brett Hauber
JBJohn F. P. Bridges
John F. P. Bridges
Introduction: The recent endorsement of discrete-choice experiments (DCEs) and other stated-preference methods by regulatory and health technology assessment (HTA) agencies has placed a greater focus on demonstrating the validity and reliability of preference results. Areas covered: We present a practical overview of tests of validity and reliability that have been applied in the health DCE literature and explore other study qualities of DCEs. From the published literature, we identify a variety of methods to assess the validity and reliability of DCEs. We conceptualize these methods to create a conceptual model with four domains: measurement validity, measurement reliability, choice validity, and choice reliability. Each domain consists of three categories that can be assessed using one to four procedures (for a total of 24 tests). We present how these tests have been applied in the literature and direct readers to applications of these tests in the health DCE literature. Based on a stakeholder engagement exercise, we consider the importance of study characteristics beyond traditional concepts of validity and reliability. Expert commentary: We discuss study design considerations to assess the validity and reliability of a DCE, consider limitations to the current application of tests, and discuss future work to consider the quality of DCEs in healthcare.

1 June 2020 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
EJEllen M Janssen
Ellen M Janssen
SDSydney M Dy
Sydney M Dy
AMAlexa Meara
Alexa Meara
PKPeter J Kneuertz
Peter J Kneuertz
CPCarolyn J Presley
Carolyn J Presley
JBJohn Fp Bridges
John Fp Bridges
Objective: Increased treatment options and longer survival for lung cancer have generated increased interest in patient preferences. Previous studies of patient preferences in lung cancer have not fully explored preference heterogeneity. We demonstrate a method to explore preference heterogeneity in the willingness of patients with lung cancer and caregivers to trade progression-free survival (PFS) with side effects. Patients and Methods: Patients and caregivers attending a national lung cancer meeting completed a discrete-choice experiment (DCE) designed through a collaboration with patients. Participants answered 13 choice tasks described across PFS, short-term side effects, and four long-term side effects. Side effects were coded as a one-level change in severity (none-mild, mild-moderate, or moderate-severe). A mixed logit model in willingness-to-pay space estimated preference heterogeneity in acceptable tradeoffs (time equivalents) between PFS and side effects. The study was reported following quality indicators from the United States Food and Drug Administration’s patient preference guidance. Results: A total of 87 patients and 24 caregivers participated in the DCE. Participants would trade 3.7 month PFS (95% CI (CI): 3.3– 4.1) for less severe functional long-term treatment side effects, 2.3 months for less severe physical long-term effects (CI: 1.9– 2.8) and cognitive long-term effects (CI: 1.8– 2.8), 0.9 months (CI: 0.4– 1.4) for less severe emotional long-term effects, and 1.8 months (CI: 1.4– 2.3) for less severe short-term side effects. Most participants (90%) would accept treatment with more severe functional long-term effects for 8.4 additional month PFS. Conclusion: Participants would trade PFS for changes in short-term side effects and long-term side effects, although preference heterogeneity existed. Lung cancer treatments that offer less PFS but also less severe side effects might be acceptable to some patients.

1 October 2018 in Value in Health
Verified
Journal Article
Closed access
TTTommi Tervonen
Tommi Tervonen
TSTabea Schmidt-Ott
Tabea Schmidt-Ott
KMKevin Marsh
Kevin Marsh
JBJohn F.P. Bridges
John F.P. Bridges
MQmatthew quaife
matthew quaife
EJEllen Janssen
Ellen Janssen